Charles Link

Charles Link has an extensive work experience in the pharmaceutical and biotechnology industry. Charles is the founder, president, and chief medical officer of Syncromune since December 2020. In addition, they are the founder and chairman of ChainLink Pharma since January 2021. Charles also serves as a board member of Viewpoint Molecular Targeting, Inc. since March 2021 and as a member of the board of directors of QSAM Biosciences, Inc. since February 2021. Previously, they founded and served as the CEO of BioProtection Systems Corporation from January 2010 to August 2019. Prior to that, Charles was the founder, chairman, and CEO of NewLink Genetics from July 1999 to August 2019.

Charles Link's education history includes attending Stanford University School of Medicine, where they did not specify a start or end year or a degree or field of study. Charles also participated in the Medical Oncology Residency Program at the National Cancer Institute (NCI) with no given dates or degree name. Charles earned a Bachelor's degree from Stanford University, and finally, they pursued Chemistry at the United States Air Force Academy, again without specified dates or a degree.